BSIM Therapeutics

BSIM Therapeutics is a Portuguese biotechnology company founded in 2011 as a spinoff from the University of Coimbra.

The company is dedicated to discovering and developing small-molecule drug candidates for transthyretin-mediated amyloidosis (TTR) and its related clinical manifestations. BSIM Therapeutics aims to address unmet medical needs in rare neurodegenerative diseases by creating organ-targeted therapies that provide better cost-benefit ratios than existing options. The company specializes in computer-driven drug discovery, utilizing advanced computational methodologies to enhance the discovery and optimization of new drug candidates. Their pipeline includes treatments for hereditary ATTR amyloidosis with polyneuropathy and cardiomyopathy, as well as wild-type ATTR amyloidosis. BSIM Therapeutics is committed to developing therapies that target previously untreated clinical manifestations, including central nervous system complications and oculopathy. The leadership team includes CEO Rui Brito and CTO Carlos Simões, and the company is supported by various investors, including Portugal Ventures and Bluepharma.